Gerhard Oremek1, Hildegund Sauer-Eppel, Martina Klepzig. 1. Department of Laboratory Medicine, Hospital of the Johann Wolfgang Goethe University, Theodor-Stern-Kai 7, D-60590 Frankfurt am Main, Germany.
Abstract
BACKGROUND: The aim of this study was the investigation of the diagnostic value of the amino-terminal propeptide of type I collagen (P1NP) and the tumour markers, CA 15-3 and CA 125, in patients with breast and ovarian cancer. PATIENTS AND METHODS: Serum levels of P1NP, CA 15-3 and CA 125 were analyzed using specific immunoassays. Baseline serum samples of 66 patients with metastatic breast cancer and 34 patients with metastatic ovarian cancer under chemotherapy were investigated. RESULTS: P1NP concentrations were elevated in up to 70% of patients with confirmed bone metastases. The P1NP levels were significantly higher in patients with bone metastases (median: 134 ng/ml) than in those without bone spread (median: 58.5 ng/ml). CONCLUSION: Markers of biochemical bone remodeling can be used in assessing and managing patients with malignancies that metastasize to bone. These markers are abnormally raised in the blood of patients with metastatic bone disease.
BACKGROUND: The aim of this study was the investigation of the diagnostic value of the amino-terminal propeptide of type I collagen (P1NP) and the tumour markers, CA 15-3 and CA 125, in patients with breast and ovarian cancer. PATIENTS AND METHODS: Serum levels of P1NP, CA 15-3 and CA 125 were analyzed using specific immunoassays. Baseline serum samples of 66 patients with metastatic breast cancer and 34 patients with metastatic ovarian cancer under chemotherapy were investigated. RESULTS: P1NP concentrations were elevated in up to 70% of patients with confirmed bone metastases. The P1NP levels were significantly higher in patients with bone metastases (median: 134 ng/ml) than in those without bone spread (median: 58.5 ng/ml). CONCLUSION: Markers of biochemical bone remodeling can be used in assessing and managing patients with malignancies that metastasize to bone. These markers are abnormally raised in the blood of patients with metastatic bone disease.
Authors: Ana Laura Soares; Sérgio Simon; Luiz Henrique Gebrim; Afonso Celso P Nazário; Marise Lazaretti-Castro Journal: Support Care Cancer Date: 2019-08-29 Impact factor: 3.603
Authors: Marlon O Coulibaly; Debra L Sietsema; Travis A Burgers; Jim Mason; Bart O Williams; Clifford B Jones Journal: Crit Rev Eukaryot Gene Expr Date: 2010 Impact factor: 1.807
Authors: Windy Dean-Colomb; Kenneth R Hess; Elliana Young; Terrie G Gornet; Beverly C Handy; Stacy L Moulder; Nuhad Ibrahim; Lajos Pusztai; Daniel Booser; Vicente Valero; Gabriel N Hortobagyi; Francisco J Esteva Journal: Breast Cancer Res Treat Date: 2012-12-15 Impact factor: 4.872